Skip to main content
Search
Search
Anywhere
Quick Search anywhere
Enter words / phrases / DOI / ISBN / keywords / authors / etc
Search
Advanced Search
Login
Skip main navigation
Open Drawer Menu
Close Drawer Menu
Home
Journal of Comparative Effectiveness Research
Journal of Patient Centricity
The Evidence Base
Skip slideshow
Journal of Comparative Effectiveness Research
ISSN (print): 2042-6305 • ISSN (online): 2042-6313
Impact Factor: 2.5 (2024) • CiteScore: 3.8 (2024) • Open Access
Read more
Journal of Patient Centricity
ISSN (online): 2978-8579
In partnership with the PCSIG • Open Access
Read more
The Evidence Base
Latest news, opinion and insight into hot topics including RWE, HEOR, HTA and market access
Read more
Latest
The value of time savings in breast cancer therapy for patients and healthcare providers: the subcutaneous injection of pertuzumab and trastuzumab fixed-dose combination at a tertiary care center in the UAE
Khaled H.A. Al Qawasmeh
Journal of Comparative Effectiveness Research
2 Jun 2026
Directly comparing randomized and real-world controls in adjuvant breast cancer
Brigham Walker
,
Marley Boyd
,
Michelle Silver
,
Junxin Shi
,
Purva Bulsara
,
Nino Balanchivadze
, and
Nicholas J Robert
Journal of Comparative Effectiveness Research
29 May 2026
Editor’s highlights from the
Journal of Comparative Effectiveness Research
– June 2026
The Evidence Base
New debate calls for collaboration to safeguard cancer patient access amid MFN pricing uncertainty
The Evidence Base
Journal of Comparative Effectiveness Research
Open access, peer-reviewed journal offering rapid publication for all aspects of HEOR and related areas
Read More
FROM THE EVIDENCE BASE
Editor’s highlights from the
Journal of Comparative Effectiveness Research
– June 2026
Insights into ALZ-NET and real-world evidence generation in Alzheimer’s disease: A conversation with Rebecca Edelmayer, Alzheimer's Association
Improving transparency in target trial emulation: The TARGET guideline with Aidan Cashin, University of New South Wales
Improving transparency in target trial emulation: The TARGET guideline with Aidan Cashin, University of New South Wales
Comparing general-purpose and domain-specific AI in confounder identification for HTA submissions
Spain approves national HTA framework aligned with EU HTAR under new Royal Decree
Editor’s highlights from the
Journal of Comparative Effectiveness Research
– June 2026
How US drug pricing reforms are reshaping biopharma investment and innovation
Trump administration broadens TrumpRx.gov to include generic medicines
The Evidence Base
Online hub providing the latest news, opinion and insights into HEOR, RWE, HTA and more
Read More
FROM THE EVIDENCE BASE
Editor’s highlights from the
Journal of Comparative Effectiveness Research
– June 2026
New debate calls for collaboration to safeguard cancer patient access amid MFN pricing uncertainty
Insights into ALZ-NET and real-world evidence generation in Alzheimer’s disease: A conversation with Rebecca Edelmayer, Alzheimer's Association
Improving transparency in target trial emulation: The TARGET guideline with Aidan Cashin, University of New South Wales
.png)
.png)
